Tay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders.
Tag Archive for: licensing
Neurimmune has entered into a collaboration and license agreement with AstraZeneca subsidiary Alexion Pharmaceuticals to commercialise its antibody NI006.